Early detection, disease prognosis, a guide to treatment, a key to unlock the secrets of how cancers evolve. Researchers have high hopes for what they can learn from the biological detritus shed by primary tumours and metastases.
Our new vocabulary Â– gene, genome, molecular, targeted, personalised Â– no longer inspires the confidence it once did, and as the cancer community prepares to gather at the 18th ECCO - 40th ESMO European Cancer Congress in Vienna, there is a real sense of uncertainty about where the next major progress will come from, writes Alberto Costa in this editorial.
Denis Lacombe quietly orchestrating the clinical research revolution
The scientific complexity and economic cost of developing new cancer therapies demand a level of collaboration and sharing that takes both industry and academia well beyond their comfort zones. EORTC head Denis Lacombe believes he has the passion and the vision to help make it happen.
Recognising and reducing the risk of chemotherapy extravasation
When chemotherapy drugs leak from the veins it can cause serious injury to the
patient, greatly heighten their fears of undergoing future treatment cycles, and
undermine their trust in their medical team. Knowing how to assess and reduce
the risks, and what to do when things go wrong, is essential.